Neurocrine Biosciences (NBIX) Q1 2024 Earnings
Neurocrine Biosciences reported Q1 2024 revenue of $515.3M, beat analyst consensus of $512.4M by $2.9M. Diluted EPS came in at $0.42, missed the $1.01 consensus by $0.59. Neurocrine Biosciences reports across 2 business segments, led by Commercial Products and Clinical Development Pipeline.
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Neurocrine Biosciences's Q1 2024 earnings report.
Neurocrine Biosciences (NBIX) reported Q1 2024 earnings on May 1, 2024 before market open.
Neurocrine Biosciences reported revenue of $515.3M and diluted EPS of $0.42 for Q1 2024.
Revenue beat the consensus estimate of $512.4M by $2.9M. EPS missed the consensus estimate of $1.01 by $0.59.
You can read the 10-Q periodic report (0000914475-24-000117) directly on SEC EDGAR. The filing index links above go to sec.gov.